EATG » News

Call for organisations and activists to present at the European NGO booth (world AIDS 2018 conference)

We are happy to invite organisations and activists in Europe and Central Asia to present, discuss, share and learn at European NGO booth at the world AIDS 2018 Amsterdam conference.…

EATG launches a report on access to HCV-related services in prison settings in Europe

Today, the European AIDS Treatment Group launches a report along with recommendations on access to HCV-related services in prison settings in Europe. At the same time, a pilot Spring European…

Civil society organizations come forth with a Joint Statement in advance of the 39th meeting of the Global Fund Board

With a joint statement addressed to the Global Fund, more than 40 international, regional and national organizations have voiced their deep concerns regarding Global Fund's eligibility policy and the limitations…

Ageing with HIV: New challenges and unmet needs of people aged 18 – 50 years living and ageing with HIV/AIDS (3-6 May 2018, Kiev)

The closing meeting from the third phase of the Ageing with HIV project is kicking off tomorrow in Kiev and will run until Sunday. We are excited to welcome 94…

Webinar: Results of the METRODORA research on the involvement of women in HIV clinical trials

EATG will host a webinar on the Results of the METRODORA research on the involvement of women in HIV clinical trials on Wednesday, 02 May 2018, 13:00 – 14:00 CEST…

Webinar: Introduction to medicine research and development

EATG will host a webinar, Introduction to medicine research and development, on Thursday, 26 April 2018, 18:00 – 19:00 CEST (Brussels, Berlin, Paris time). The webinar will be led by…

Positive Stories: the voices of women living with HIV across Europe

The EATG has launched a new initiative aiming to give women living with or affected by HIV a platform to make their voices heard. Positive Stories is an empowerment tool…

Grindr sharing the HIV status and other personal information of their users with third parties without their informed consent is unacceptable

The EATG is disturbed by the news, reported by BuzzFeed News, about Grindr sharing the HIV status information of their users with two third companies, Apptimize and Localytics. Such actions…

PARADIGM: A collaborative initiative on patient engagement kicks-off

PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines), a new initiative regarding patient engagement in research and development of medicines, was launched this week during…

STEP-UP 2018/19: Call for participants

The European AIDS Treatment Group (EATG) is happy to launch the call for participants for the STEP-UP 2018/19 training programme today. The STEP-UP programme is designed for people living with…

Metrodora: Webinar on women’s participation in HIV research

EATG will host a webinar on women’s participation in HIV research on 4 April 2018, 17:00 – 18:00 CET (Brussels, Berlin, Paris time). The webinar is organized within the context…

Civil society and patient organisations are seeking EU leadership and action on HIV, Hepatitis and TB

The European AIDS Treatment Group, along with other civil society and patients organisations, has co-signed an open letter to Commissioner Andriukaitis in view of the upcoming Staff Working Document on…

Organisations are urging Commissioner Andriukaitis to foster EU Member States’ response to Tuberculosis

In view of upcoming World Tuberculosis (TB) Day on March 24, the TB Europe Coalition, supported by 34 civil society and community organisations, urge Commissioner Andriukaitis to make a public…

Call for WHO & UNODC to revise guidelines on International Standards for the Treatment of Drug Use Disorders

The European AIDS Treatment Group together with 188 organisations has co-signed an open letter initiative by the International Network of People who use Drugs addressed to the WHO and UNODC…

HIVACAR: EATG reports from the second general assembly of the consortium

On March 15-16 the European AIDS Treatment Group participated in the second general assembly meeting of the HIVACAR consortium in Digem (Belgium). The EATG in collaboration with the Complutense University…

Webinar: Patient-reported Outcomes (PROs)

We invite you to join the webinar on What are patient-reported outcome measures and how are they used in drug development? taking place on Tuesday, 27 March 2018, 18:00 –…

THE EU CIVIL SOCIETY FORUM ON HIV, TB AND VIRAL HEPATITIS URGES THE EUROPEAN COMMISSION TO PRIORITIZE PUBLIC HEALTH WITHIN THE UPCOMING FINANCIAL FRAMEWORK

On 6 March the EU Civil Society Forum on HIV, TB and Viral Hepatitis wrote to the European Commission President Juncker, as well as Budget and Health Commissioners, in response to the…

Metrodora: Call for applications in the Multi-Stakeholders’ Meeting

Call for applications: Multi-Stakeholders’ Meeting Meaningful Engagement of Women in HIV Treatment Research Wednesday 16 May 2018, Park Inn Hotel, Brussels, Belgium   The Meeting: Within the framework of the…

The EU Civil Society Forum on HIV, TB and Viral Hepatitis calls the Romanian Ministry of Health to take on a leadership role on EU viral hepatitis policies

On 26 February, the EU Civil Society Forum on HIV, TB and Viral Hepatitis wrote to the Romanian Ministry of Health to request that it uses its convening power and…

HIV prevention: It’s time to stop accepting the status quo, PrEP Summit concludes

The biggest barrier to HIV pre-exposure prophylaxis (PrEP) becoming more available and more widely used is not cost so much as widespread acceptance of the status quo in HIV prevention,…

Study sheds more light on delamanid role in treating MDR-TB

A phase 3 trial of delamanid, a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found no statistically significant reduction in time to sputum culture conversion when compared to placebo,…

Urokinase plasminogen receptor levels linked to non-AIDS related events during ART viral suppression

In patients with HIV, elevated levels of soluble urokinase plasminogen activator receptor are associated with non-AIDS events, according to study results published in Clinical Infectious Diseases. The study included participants with…

Accelerating the elimination of viral hepatitis: The Lancet Gastroenterology & Hepatology Commission

A global panel of experts have published their key recommendations to advance the fight against viral hepatitis. The Commission, published in The Lancet Gastroenterology & Hepatology, assesses the global landscape…

Air pollution may worsen brain function in HIV-infected children

Study explores cost-effectiveness of conception strategies for HIV serodiscordant couples

A new multi-institutional study has examined the cost-effectiveness of the pre-exposure prophylaxis (PrEP) combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and assisted reproductive options for serodiscordant couples with an…

For young women in Sub-Saharan Africa addressing transactional sex may be key to reducing HIV infections

Young women in sub-Saharan Africa are at a disproportionately high risk for HIV infection. Engagement in transactional sex may contribute to this increased HIV prevalence according to a new report…

Potential drug interactions among people with HIV taking statins

Drug interactions remain a potential problem for HIV-positive people who are treated with statins, according to research published in the December issue of the Journal of the American Heart Association. Potential…

HIV/STI counseling and testing for patients on PrEP

Further efforts are needed to educate and prepare healthcare providers to prescribe preexposure prophylaxis (PrEP) and manage patients receiving PrEP to reduce the risk for acquiring HIV infection, according to…

HIV viremia, CD4 count determine response to hepatitis A vaccine

Nearly 4% of patients with HIV who received hepatitis A vaccinations during an outbreak demonstrated seroreversion, most of whom had HIV viremia and lower CD4 lymphocyte counts compared with those…

‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

To look at Nelson Vergel, you would never guess what he has been through. For 35 years, he has kept up a relentless fight against HIV, but his muscular physique…

Dolutegravir monotherapy for HIV no longer recommended: study

Dolutegravir monotherapy should no longer be used as HIV maintenance therapy, according to Bart J.A. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, both from Erasmus Medical Center, Rotterdam, the…

January 2019 issue of The Lancet HIV now online

The Lancet HIV is an exclusively online journal dedicated to publishing original research that advocates change in, or illuminates, HIV clinical practice. It publishes translational, epidemiological, clinical, operational, and implementation…

Imperial takes the lead on a global study of HIV-associated liver cancer

Research from the Liver Cancer Research Group at Imperial has shed new light on the natural course of liver cancer in people living with HIV. In a report recently published…

The road ahead for HIV cure research

Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view. Read an article by Benjamin Ryan in POZ here.…

Cancer concerns in people with HIV

Researchers looked both at the first and second time people with HIV have been diagnosed with cancer. People with HIV are increasingly being diagnosed with a non-AIDS-defining cancer for a…

‘RAPID’ HIV treatment initiation a success in San Francisco

Populations considered hard to treat or engage in care can benefit from same-day antiretroviral treatment as part of a clinic offering social safety-net interventions. High rates of viral suppression are…

Growth in positive attitudes towards PrEP among Australian gay and bisexual men

Willingness to consider using pre-exposure prophylaxis (PrEP) increased between 2011 and 2017 among gay and bisexual men in Australia, while concerns about using it decreased, according to research published in AIDS…

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

The U.S. Supreme Court on Monday handed a defeat to Merck & Co by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and…

USPSTF recommends HBV screening in pregnant women

The U.S. Preventive Services Task Force has released a draft recommendation that pregnant women be screened for hepatitis B virus infection at the first prenatal visit to prevent infection in…

Baseline viral load suboptimal in predicting elbasvir/grazoprevir efficacy

Baseline testing for nonstructural protein 5A (NS5A) resistance-associated substitutions enables more patients to receive 12 weeks of elbasvir/grazoprevir therapy without compromising the opportunity for sustained virologic response when compared with…